OncoMatch/Clinical Trials/NCT06193889
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Is NCT06193889 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including KYV-101 and Standard of Care Treatment for myasthenia gravis.
Treatment: Standard of Care Treatment · Standard lymphodepletion regimen · KYV-101 — A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CHRNA1 autoantibody
Presence of autoantibodies to AChR or MuSK at screening
Required: MUSK autoantibody
Presence of autoantibodies to AChR or MuSK at screening
Demographics
Prior therapy
Must have received: immunosuppressive or immunomodulatory therapy
Failed treatment with 2 or more immunosuppressive/immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (>4 times/year over ≥12 months) to control symptoms
Cannot have received: anti-CD20 monoclonal antibody (rituximab)
No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening
Cannot have received: anti-CD19 monoclonal antibody
No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening
Cannot have received: FcRn inhibitor
No use of FcRn inhibitors within 4 weeks prior to screening
Cannot have received: gene therapy product
Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target
Cannot have received: cellular immunotherapy
Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Irvine · Orange, California
- Stanford University Medical Center · Palo Alto, California
- University of Miami · Miami, Florida
- Indiana University Health · Indianapolis, Indiana
- Thomas Jefferson University Hospital · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06193889 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD20 monoclonal antibody, anti-CD19 monoclonal antibody, FcRn inhibitor disqualifies patients from enrollment.
Does this trial require CHRNA1?
Yes, CHRNA1 autoantibody is a required biomarker for enrollment.
Does this trial require MUSK?
Yes, MUSK autoantibody is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify